Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).
Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.
In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products.
...
Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications
&nbs...
Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC develope...
It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of...
Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors.
...
Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives.
Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years.
...
In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers.
&nbs...
Given the need for accelerated bioprocessing operations, low-volume bioreactors have emerged as a relatively economic solution for parallelized cell cultivations and applications ranging from media development to process optimization
The success of currently employed artificial intelligence (AI) solutions has encouraged researchers to explore the potential of such technologies in the healthcare sector, with its prime focus being oncology, to enable the treatment of several prevalent m...
Given their ability to cater to the existing unmet needs in the healthcare sector, various industry stakeholders have made investments for the development and implementation of precision medicine software applications for diagnosis, analysis and treatment...
The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, cert...
The current landscape of biologics fill / finish contract service providers features the presence of several established and emerging players, with a diverse set of production capabilities. The fill / finish services market is presently dominated by servi...
